Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16111 ↗At a glance
Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2025. Written by Yiqin Wang and 5 co-authors. Institution: Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glycemic Control, Hypoglycemic Agents. Cited 1 times so far (Crossref); 32 references. Funded by: Key Laboratory of National Health Commission, and Key Laboratory of Nephrology, Guangdong Province, Guangzhou, China, National Natural Science Foundation of China-Guangdong Joint Fund, National Key Research and Development Project of China.
Topics: Diabetes mellitus
Abstract (original language)
Aims
The ACCORD trial showed that intensive glucose‐lowering therapy has a limited impact on renal function decline. We aimed to identify subgroups in the ACCORD population that might derive renal benefits from intensive glucose‐lowering therapy. Materials and Methods The primary renal outcome included a ≥50% decline in baseline estimated glomerular filtration rate or end‐stage renal disease (ESRD). Using the causal tree model, we employed internal cross‐validation to identify five pivotal variables influencing the renal efficacy of intensive glycaemic control. These variables were integrated into the model‐based recursive partitioning approach, yielding a visualizable tree model that depicted benefitting subgroups.
Results
Node 4, characterized by no cardiovascular history, systolic blood pressure (SBP) ≤142.67 mm Hg, and triglycerides ≤172 mg/dL, showed significantly reduced hazards of the composite renal outcome (fully adjusted hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.49–0.89; p = 0.006) and doubling of serum creatinine (fully adjusted HR 0.59, 95% CI 0.36–0.98; p = 0.041). Node 7 (no cardiovascular history and SBP 142.67–154 mm Hg) showed reduced hazards of the primary renal outcome (fully adjusted HR 0.67, 95% CI 0.49–0.93; p = 0.016) and ESRD (fully adjusted HR 0.35, 95% CI 0.17–0.74; p = 0.0057). Encouragingly, neither node 4 nor node 7 displayed elevated cardiovascular risk or hypoglycaemic events.
Conclusions
Through innovative machine learning, we identified ACCORD subgroups benefitting significantly from intensive glycaemic therapy for renal outcomes, without increased cardiovascular or hypoglycaemic risks.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.
ORCID profiles: Wei Chen
Funding
- Key Laboratory of National Health Commission, and Key Laboratory of Nephrology, Guangdong Province, Guangzhou, China
- National Natural Science Foundation of China-Guangdong Joint Fund
- National Key Research and Development Project of China
- 5010 Clinical Program of Sun Yat-Sen University
- Guangzhou Science and Technology Project
- Natural Science Foundation of Guangdong Province, China
- Natural Science Foundation of Guangdong Province
Cite
APA
Wang, Y., Wen, Q., Lu, Y., Yang, J., Huang, N., & Chen, W. (2025). Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16111
Vancouver
Wang Y, Wen Q, Lu Y, Yang J, Huang N, Chen W. Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16111
BibTeX
@article{Wang2025,
author = {Wang, Yiqin and Wen, Qiong and Lu, Yuewen and Yang, Jiayi and Huang, Naya and Chen, Wei},
title = {Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16111}
}
EUVIMED